All In Biotech

Drug Trial Radar · NCT03599245

This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,055

Actual

Start

Jul 12, 2018

Primary completion

Jul 17, 2025

Study completion Jul 17, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).

Conditions

  • Multiple Sclerosis

Interventions

  • OcrelizumabDrug

    Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
  2. Time to Onset of CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  3. Time to Onset of CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
  4. Time to Onset of CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  5. Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
  6. Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  7. Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
  8. Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  9. Percentage of Participants Who Had Confirmed Disability Improvement (CDI) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
  10. Percentage of Participants Who Had CDI Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  11. Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96Time frame: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
  12. Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  13. Percentage of Participants Who Had Improved, Stable or Worsened Disability Compared With CASTING Baseline in EDSS Category at LIBERTO Week 96Time frame: At LIBERTO Week 96
  14. Percentage of Participants Who Had Stable or Worsened Disability Compared With ENSEMBLE Baseline in EDSS Category at LIBERTO Week 96Time frame: At LIBERTO Week 96
  15. Change From CASTING Baseline in EDSS Score to LIBERTO Week 96Time frame: CASTING Baseline to LIBERTO Week 96 (up to 4 years)
  16. Change From ENSEMBLE Baseline in EDSS Score to LIBERTO Week 96Time frame: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  17. Time to ≥ 20% Increase in 25-foot Walk Test (T25FWT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  18. Time to ≥ 20% Increase in 25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  19. Time to ≥ 20% Increase in 9 Hole Peg Test (9HPT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  20. Time to ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  21. Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  22. Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  23. Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
  24. Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96Time frame: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Locations

161 sites in 26 countries. Site status is shown where the registry gives one.

  • Hospital Churruca Visca

    Buenos Aires, Argentina

  • Centro de Especialidades Neurológicas y Rehabilitación - CENyR

    Ciudad Autonoma Buenos Aires, Argentina

  • Fundacion Rosarina de Neurorehabilitacion

    Rosario, Argentina

  • AZ Sint Jan

    Bruges, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • CHU Tivoli

    La Louvière, Belgium

  • CHU de Liège (Sart Tilman)

    Liège, Belgium

  • Revalidatie en MS Centrum

    Overpelt, Belgium

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clinicas - FMUSP

    São Paulo, São Paulo, Brazil

  • Shat Np Sveti Naum

    Sofia, Bulgaria

  • Multiprofile Hosp. for Active Treatment

    Sofia, Bulgaria

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre Uni Campus

    London, Ontario, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Clinique NeuroOutaouais

    Gatineau, Quebec, Canada

  • Recherche Sepmus Inc.

    Greenfield Park, Quebec, Canada

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, Canada

  • Clinical Hospital Centre Zagreb

    Zagreb, Croatia

  • Fakultni nemocnice u sv. Anny

    Brno, Czechia

  • Nemocnice Jihlava

    Jihlava, Czechia

  • VFN Praha Poliklinika Rs Centrum - Budova A

    Prague, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Aalborg Universitetshospital

    Aalborg, Denmark

  • Aarhus Universitetshospital

    Aarhus N, Denmark

  • Rigshospitalet Glostrup

    Glostrup Municipality, Denmark

  • Odense Universitetshospital, Neurologisk Afdeling N

    Odense C, Denmark

  • Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken

    Sønderborg, Denmark

  • East Tallinn Central Hospital

    Tallinn, Estonia

  • West Tallinn Central Hospital

    Tallinn, Estonia

  • Tartu University Hospital

    Tartu, Estonia

  • Mehiläinen Neo Turku

    Turku, Finland

  • CHU de Besancon Hopital Jean Minjoz

    Besançon, France

  • Groupe Hospitalier Pellegrin

    Bordeaux, France

  • Hopital neurologique Pierre Wertheimer - CHU Lyon

    Bron, France

  • Hopital Gabriel Montpied CHU de Clermont-Ferrand

    Clermont-Ferrand, France

  • CH de Gonesse

    Gonesse, France

  • CHU de Grenoble

    La Tronche, France

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.